Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2020 | The potential of RegenMed in the oncology space

Helen Tayton-Martin • 15 Oct 2020
Meeting on the Mesa 2020
General

Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, speaks on the reformative nature of regenerative medicine. Dr Taytor-Martin highlights cell and gene therapies in the oncology setting, and how these technologies may represent a potential paradigm shift in the future. This interview took place during the 2020 Meeting on the Mesa congress.

More from Helen Tayton-Martin

6:02
Adaptimmune: SPEAR T-cells
Helen Tayton-Martin • 15 Oct 2020
4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
3:12
The cell therapy landscape: disruptive technologies
Helen Tayton-Martin • 15 Oct 2020

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals